articleScience Translational MedicineMar 18, 2015GREEN OA

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma

SHSiwen Hu‐LieskovanSMStephen MokBHBlanca Homet MorenoJTJennifer TsoiLRLídia Robert

University of California, Los Angeles · Instituto de Salud Carlos III · +4 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Combining immunotherapy and BRAF targeted therapy may result in improved antitumor activity with the high response rates of targeted therapy and the durability of responses with immunotherapy. However, the first clinical trial testing the combination of the BRAF inhibitor vemurafenib and the CTLA4 antibody ipilimumab was terminated early because of substantial liver toxicities. MEK [MAPK (mitogen-activated protein kinase) kinase] inhibitors can potentiate the MAPK inhibition in BRAF mutant cells while potentially alleviating the unwanted paradoxical MAPK activation in BRAF wild-type cells that lead to side effects when using BRAF inhibitors alone. However, there is the concern of MEK inhibitors being…

Citation impact

566
total citations
FWCI
26.65
Percentile
100%
References
44
Citations per year

Authors

11

Topics & keywords

Topics
Keywords
  • Melanoma
  • Immunotherapy
  • Cancer research
  • Medicine
  • Vemurafenib
  • Metastatic melanoma
  • Cancer
  • Internal medicine
No related works found for this paper.

Funding